![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cytomyx Hldgs | LSE:CYX | London | Ordinary Share | GB0033942276 | ORD 2.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.10 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:4103R Cytomyx Holdings PLC 19 September 2005 For immediate release 19 September 2005 CYTOMYX HOLDINGS PLC ("Cytomyx" or "the Company") Cytomyx sells distribution business for #900,000 to focus on drug discovery technologies Cytomyx Holdings plc (AIM: CYX), the leading provider of drug discovery products and services, announced today that it has sold Cambridge BioScience Limited (" Cambridge BioScience"), its research products distribution business, to Alan Seeley, a former director of and current shareholder in Cytomyx and the founder of Cambridge BioScience. Cambridge BioScience markets research products on behalf of a range of predominantly US-based manufacturers within the UK and was acquired by Cytomyx in 2002. In the year ended 30 September 2004, Cambridge BioScience reported a pre-tax profit of #190,282 on revenues of #2,992,061. As at 31 March 2005, the date of the last unaudited interim balance sheet, Cambridge BioScience had net assets of #390,275 and made a pre-tax loss of #61,660 on revenues of #975,427. Mr Seeley has acquired the business through the purchase of the entire share capital of Cambridge BioScience. The aggregate consideration paid was #900,000, satisfied as to #150,000 in cash and the assumption of #750,000 of outstanding loan notes due to Mr Seeley by Cambridge BioScience from the acquisition of the business of Cambridge BioScience from him in 2002. The net proceeds of the disposal will be applied to working capital for the Company. The Directors of Cytomyx, having consulted with the Company's nominated adviser, Corporate Synergy plc, consider that the terms of the disposal are fair and reasonable so far as shareholders are concerned. Commenting on the disposal, Mike Kerins, Cytomyx' Chief Executive, said: "The sale of Cambridge BioScience is consistent with our strategy of building a leading, technology based, drug discovery solutions provider. We now have a clear focus on developing technologies that enhance drug discovery productivity. "Our US operations use human tissue samples to identify the link between genes and disease to help our clients in the pharmaceutical industry to develop highly targeted drugs. Our UK business has established itself as the world's leading developer of ion channel cell lines, which can be used to develop safer drugs by eliminating those that may fail in clinical development due to toxicity associated with interactions with ion channels in the heart." For further information, please contact: Cytomyx Holdings plc 01223 508191 Mike Kerins, Chief Executive Buchanan Communications 020 7466 5000 Mark Court/Mary-Jane Johnson Notes to Editors About Cytomyx Holdings Cytomyx Holdings plc is a rapidly growing life science company based in Cambridge, UK. The Company's primary focus is on developing novel technologies that assist pharmaceutical and biotechnology companies in their efforts to develop new treatments more effectively. The company does this by providing solutions that provide early insights into the likely efficacy and safety profile of new drugs in development. The Company has two main areas of expertise: the use of human clinical samples in understanding the linkage between gene expression and disease and the development of cell-based assays that are used to support ion channel drug discovery and predict potential cardiac toxicity in new drugs. Cytomyx is listed on the AIM market of the London Stock Exchange (CYX.L). For more information visit www.cytomyx-holdings.com This information is provided by RNS The company news service from the London Stock Exchange END DISSFDFAMSISESU
1 Year Cytomyx Chart |
1 Month Cytomyx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions